STOCK TITAN

Harrow Health Inc - HROW STOCK NEWS

Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.

Company Overview

Harrow Health Inc (HROW) is an innovative eyecare pharmaceutical company focused on addressing unmet medical needs through the discovery, development, production, and commercialization of specialized ophthalmic formulations and therapeutic products across the United States. Operating at the intersection of advanced research and clinical application, the company brings together deep industry expertise, rigorous R&D, and a commitment to improving patient care.

Business Model and Operations

At its core, Harrow Health provides a comprehensive portfolio that blends ophthalmology-based drug development with non-intravenous sedation and anesthesia therapeutics for a variety of medical procedures. Its operations are structured around:

  • Ophthalmic Therapeutics: Focusing on the management of ocular surface diseases, the company develops topical eye drop formulations that serve both preventative and therapeutic roles.
  • Compounded Medications: Offering both sterile and non-sterile formulations, it meets the needs of physicians seeking tailored solutions for diverse clinical scenarios.
  • Non-Intravenous Sedation: Developing products designed to facilitate conscious sedation during procedures such as cataract surgery, thereby enhancing patient comfort and procedural efficiency.

This multi-pronged approach not only diversifies its product portfolio but also creates a resilient business model that appeals to healthcare professionals and institutions across outpatient, in-office, and hospital settings.

Market Position and Competitive Landscape

Harrow Health Inc has carved a niche within the highly regulated US pharmaceutical market. Its strategic focus on ocular and sedation therapeutics differentiates it from broader scale pharmaceutical companies, while its commitment to advanced research and quality production standards reinforces its reputation among eyecare professionals. In a competitive landscape where precision and safety are paramount, Harrow Health’s integration of clinical insights with innovative drug formulations positions it as a noteworthy player devoted to addressing specific medical challenges effectively.

Product Portfolio and Therapeutic Solutions

The company has developed an extensive range of products that address conditions related to the ocular surface and procedural sedation. Its portfolio includes:

  • Topical Ophthalmic Formulations: Designed to manage diseases affecting the ocular surface and support rehabilitation of vision-related functions.
  • Compounded Medications: Both sterile and non-sterile, these are tailored to meet precise medical requirements across various treatment settings.
  • Sedation Therapeutics: Products intended for sublingual administration provide non-intravenous sedation, enabling safe and effective patient management during surgical procedures.

Research, Development, and Quality Assurance

The foundation of Harrow Health Inc’s operations lies in robust research and development. The company continually refines its product offerings through comprehensive clinical research and adherence to stringent quality assurance protocols. Its approach underscores a commitment to safety and efficacy while addressing the evolving needs of healthcare providers and patients. This rigorous scientific methodology exemplifies the company’s dedication to maintaining high standards of regulatory compliance and industry best practices.

Commitment to Scientific Integrity and Patient Care

Across its diverse operations, Harrow Health demonstrates a sustained commitment to improving patient outcomes. The company’s emphasis on continuous innovation, strategic R&D, and quality-focused manufacturing processes helps ensure that its pharmaceutical solutions not only meet but often exceed industry benchmarks. This dedication to scientific integrity and patient well-being has established Harrow Health as a trusted entity within the field of eyecare therapeutics.

Strategic Value Proposition

Harrow Health Inc’s value proposition is rooted in its specialized expertise in ophthalmic formulations and sedation therapies. By addressing critical gaps in current medical treatments, the company supports healthcare providers in delivering effective and accessible care. Its balanced focus on innovation, quality, and clinical relevance positions it as a vital contributor to the pharmaceutical landscape, particularly within the realms of eye care and procedural sedation.

Overall, Harrow Health Inc exemplifies a dedicated, research-driven approach to pharmaceutical development that leverages deep industry expertise to meet unmet medical needs. Through its integrated operations and commitment to quality, it remains a significant, unbiased source of therapeutic solutions for healthcare professionals nationwide.

Rhea-AI Summary

Harrow (Nasdaq: HROW), a prominent North American eyecare pharmaceutical company, will participate in two investor conferences in May. The company will attend the B. Riley Securities 24th Annual Institutional Investor Conference at the Beverly Hilton Hotel in Beverly Hills, CA, on May 22-23, 2024. The event includes an in-person Fireside Chat and 1x1 investor meetings.

Harrow will also be present at the Craig-Hallum 21st Annual Institutional Investor Conference at the Depot Renaissance Hotel in Minneapolis, MN, on May 29, 2024, featuring 1x1 and small group investor meetings. Interested investors should contact their B. Riley or Craig-Hallum representative for meeting arrangements. Neither event will be webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
conferences
-
Rhea-AI Summary

Harrow (Nasdaq: HROW) reported its first quarter 2024 financial results, with revenues reaching $34.6 million, a 33% increase from the prior-year quarter. Gross margin was steady at 69%, while net loss increased to $13.6 million from $6.6 million in Q1 2023. Key highlights include IHEEZO's new CMS reimbursement approval, seven new supply agreements, and new patent claims valid through 2039. VEVYE's coverage expanded to 150 million lives, and ImprimisRx returned to quarterly growth. Cash reserves totaled $76 million as of March 31, 2024, with an additional $5.5 million from recent Eton Pharmaceuticals stock sales. Harrow remains focused on expanding its dry eye and retina franchises and stabilizing ImprimisRx.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.55%
Tags
-
Rhea-AI Summary

Harrow, a U.S. eyecare pharmaceutical company, appoints Greg DiPasquale as Senior Vice President, Head of Commercial. DiPasquale brings extensive experience from companies like Regeneron and Novartis, with a track record of growing sales and revenue in the ophthalmic pharmaceutical industry. Harrow aims to leverage DiPasquale's expertise to enhance its leadership structure and drive growth in the North American market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
none
Rhea-AI Summary
Harrow (Nasdaq: HROW) will release its first quarter 2024 financial results on May 13, 2024, followed by a conference call on May 14, 2024, to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
-
Rhea-AI Summary
Melt Pharmaceuticals, Inc. completes a Series B Preferred Stock financing of $24 million, increasing pre-money valuation by 150%. The funding will support the development of MELT-300, a non-IV, non-opioid tablet for procedural sedation. The Phase 3 program started in Q1 2024, with topline results expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.28%
Tags
none
-
Rhea-AI Summary
Harrow (HROW) reports a successful year with revenues of $130.2 million, a 47% increase from 2022, but a net loss of $(24.4 million). Adjusted EBITDA rose to $28.1 million. The company emphasizes growth in ophthalmic pharmaceuticals, launching new products and attracting talent for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
Rhea-AI Summary
Harrow (Nasdaq: HROW) to Release Financial Results for Q4 and Year-End 2023, Host Conference Call on March 20, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
-
Rhea-AI Summary
Harrow, Inc. (HROW) and Apotex Inc. announce an exclusive out-licensing agreement for ophthalmic pharmaceutical products in Canada. Apotex will market and distribute VERKAZIA and Cationorm PLUS while seeking approval for VEVYE, IHEEZO, and ZERVIATE. The partnership aims to expand product offerings, improve patient quality of life, and strengthen therapeutic options in the Canadian market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
none
-
Rhea-AI Summary
Harrow (Nasdaq: HROW) has appointed Adrienne Graves, Ph.D., and Lauren Silvernail to its Board of Directors, bringing the total number of members to six. The company aims to leverage their expertise to execute its Strategic Plan and maximize stockholder value by leveraging its dynamic product portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
management
Rhea-AI Summary
Harrow (Nasdaq: HROW) launches VEVYE® (cyclosporine ophthalmic solution) 0.1%, the first and only cyclosporine-based product indicated for treating both the signs and symptoms of dry eye disease (DED) in the U.S. VEVYE offers rapid onset with clinically and statistically meaningful improvement beginning as early as 15 days, with sustained improvement over 56 weeks. VEVYE patients have access to a 100% money-back guarantee program. The drug is powered by a unique combination of cyclosporine and a water-free semifluorinated alkane delivery vehicle, solving an unmet need for eyecare professionals treating the tens of millions of American chronic dry eye disease sufferers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none

FAQ

What is the current stock price of Harrow Health (HROW)?

The current stock price of Harrow Health (HROW) is $24.98 as of April 1, 2025.

What is the market cap of Harrow Health (HROW)?

The market cap of Harrow Health (HROW) is approximately 890.3M.

What is Harrow Health Inc's primary focus?

Harrow Health Inc is primarily focused on developing and commercializing ophthalmic formulations and non-intravenous sedation therapeutics addressing unmet medical needs in the US.

What types of products does the company offer?

The company offers a range of products including topical eye drop formulations, sterile and non-sterile compounded medications, and sublingual therapeutics for procedural sedation.

How does Harrow Health Inc generate revenue?

Revenue is generated through the discovery, development, and commercialization of specialty pharmaceutical products, primarily within the ophthalmic and sedation therapy markets.

What differentiates Harrow Health from its competitors?

Its focus on specialized ophthalmic therapies combined with a comprehensive approach to non-intravenous sedation and robust R&D efforts distinguishes it within a competitive, regulated market.

In which market does Harrow Health primarily operate?

Harrow Health operates mainly in the United States, catering to healthcare providers and patients with unmet needs in eyecare and sedation therapies.

What role does research and development play in the company?

R&D is central to the company’s strategy, driving the design, refinement, and regulatory compliance of its pharmaceutical products to ensure safety, efficacy, and quality.

How does the company support clinical practices?

By providing a diversified portfolio of specialized medications, Harrow Health supports healthcare professionals in managing ocular conditions and delivering safe sedation during medical procedures.

Can you explain the company’s approach to quality assurance?

The company emphasizes strict adherence to quality assurance protocols and regulatory standards, ensuring that all products meet high benchmarks for safety and effectiveness.
Harrow Health Inc

Nasdaq:HROW

HROW Rankings

HROW Stock Data

890.28M
30.85M
13.49%
59.11%
7.72%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
NASHVILLE